EUVIMEDEUVIMED entdecken
Crossref

Lower dose venetoclax, acalabrutinib, bortezomib and dexamethasone (LoVe ABoDe) regimen before chimeric antigen receptor T-cell Therapy in Relapsed/Refractory B-Cell Malignancies

BLOOD CELL THERAPY / The official journal of APBMT · 2026 · 9 (4)

DOI: 10.31547/bct-2026-023 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BLOOD CELL THERAPY / The official journal of APBMT, 2026.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) undergoing chimeric antigen receptor T-cell (CAR-T) therapy frequently require bridging treatment during CAR-T manufacture. Conventional salvage chemotherapy may cause significant myelosuppression, infections, organ toxicity, and deterioration in performance status, limiting successful CAR-T delivery. Targeted chemotherapy-free approaches may offer effective disease control with improved tolerability.

Methods

We evaluated a novel chemotherapy-free bridging regimen consisting of lower-dose venetoclax, acalabrutinib, bortezomib, and dexamethasone (LoVe ABoDe) in two multiply relapsed/refractory patients with R/R DLBCL awaiting CAR-T therapy. Patients were monitored closely for cytopenias, tumor lysis syndrome, infections, and hepatic toxicity. Treatment response was assessed using positron emission tomography-computed tomography (PET-CT) imaging before CAR-T infusion.

Results

Both patients had progressive active disease at presentation and achieved near-complete metabolic remission following LoVe ABoDe-based therapy prior to CAR-T infusion. Toxicities were manageable and mainly included thrombocytopenia requiring romiplostim support and platelet transfusions in one patient. No patient developed tumor lysis syndrome, febrile neutropenia, severe infection, grade ≥ 3 hepatotoxicity, or clinically significant bleeding. Both patients successfully underwent lymphodepletion and CAR-T infusion without delay. Post–CAR-T toxicities were limited to grade 1 cytokine release syndrome, with one patient requiring a single dose of tocilizumab. One patient progressed on day100, while another progressed 8 months after CAR-T but remains alive on palliative therapy at 21 months.

Conclusion

LoVe ABoDe chemotherapy-free targeted bridging can provide rapid disease debulking with acceptable safety before CAR-T therapy in R/R DLBCL. Larger prospective studies are warranted to validate these findings.

Zitieren

APA

(2026). Lower dose venetoclax, acalabrutinib, bortezomib and dexamethasone (LoVe ABoDe) regimen before chimeric antigen receptor T-cell Therapy in Relapsed/Refractory B-Cell Malignancies. BLOOD CELL THERAPY / The official journal of APBMT, 9(4). https://doi.org/10.31547/bct-2026-023

Vancouver

Lower dose venetoclax, acalabrutinib, bortezomib and dexamethasone (LoVe ABoDe) regimen before chimeric antigen receptor T-cell Therapy in Relapsed/Refractory B-Cell Malignancies. BLOOD CELL THERAPY / The official journal of APBMT. 2026;9(4). doi:10.31547/bct-2026-023

BibTeX
@article{euvimed2026,
  title = {Lower dose venetoclax, acalabrutinib, bortezomib and dexamethasone (LoVe ABoDe) regimen before chimeric antigen receptor T-cell Therapy in Relapsed/Refractory B-Cell Malignancies},
  journal = {BLOOD CELL THERAPY / The official journal of APBMT},
  year = {2026},
  volume = {9},
  number = {4},
  doi = {10.31547/bct-2026-023}
}
Kostenlos starten →